Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05778032

Biological Age Assessment in Adults With Prader-Willi Syndrome (ETABIOLPWS)

The primary objective of the study is to compare, in a cohort of obese subjects with PWS hospitalized at the Division of Auxology, Istituto Auxologico Italiano, Piancavallo (VB), Italy, the age acceleration calculated at study entry (T0) with the age acceleration measured at the end of a 3-week multidisciplinary metabolic rehabilitation program (T1).

Secondary objectives are to correlate the biological age with the anthropometric characteristics (with particular reference to the body composition), the glycometabolic picture, the main parameters and cardiovascular risk factors, the therapy (previous and concomitant) with rhGH and the cognitive function (mainly, the IQ).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

About this study

Methods Thirty adults affected by clinically diagnosed and genetically confirmed PWS are recruited, regardless of the treatment (previous or concomitant) with rhGH (F/M = 15/15; age: ≥ 18 years; BMI > 35 kg/m2), hospitalized for a period of integrated multidisciplinary metabolic rehabilitation at the Division of Auxology, Istituto Auxologico Italiano, Piancavallo (VB), Italy.

After verifying the inclusion criteria, clinical and anthropometric data will be collected, including the evaluation of body composition with bioimpedance analysis. Cognitive function will be assessed with a psychometric scale (Wechsler Adult Intelligence Scale).

Blood samples will be taken from each patient upon admission to the hospital (T0) and after 3 weeks of rehabilitation hospitalization (at the same time to reduce circadian variability) for the determination of the basal glycometabolic profile (glucose, insulin, HOMA-IR, glycated Hb , triglycerides, total cholesterol, LDL, HDL, and hsPCR), as well as circulating levels of leptin, IL-6, and TNF-α.

The samples taken will be used for DNA extraction. DNA methylation will be performed by treatment with sodium bisulphite and PCR-Pyrosequencing.

Biological age measurement Biological (epigenetic) age will be measured using the two algorithms of Zbiec-Piekarska (9) and Daunay (10), based on the level of DNA methylation in specific gene loci. To have an estimate of the epigenetic (biological) age that is independent of the chronological age, we will use a measure defined as age acceleration, from which, with statistical inference, we will calculate the age acceleration. To calculate it, a linear regression model with the chronological age as the independent variable and the epigenetic age as the dependent variable will be applied; the difference between the observed value and the one predicted by the model will constitute the age acceleration due to epigenetic effects. In the event that the epigenetic age is greater than the chronological age, the age acceleration will have a positive value expressed in years, negative if vice versa.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adult patients with PWS, clinically diagnosed and genetically confirmed, regardless of rhGH treatment (previous or concomitant)
  • age: ≥ 18 years
  • BMI > 35 kg/m2
  • hospitalization for integrated multidisciplinary metabolic rehabilitation program

Exclusion criteria

  • age < 18 years
  • BMI < 35 kg/m2

Treatment and study plan

Multidisciplinary metabolic rehabilitation program

Other

Multidisciplinary metabolic rehabilitation program with a duration of 3 weeks

Primary outcomes

  1. DNA methylation

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

    Change in level of DNA methylation

Secondary outcomes

  1. Glycometabolic profile: glucose

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

    Change in glycometabolic profile - glucose levels

  2. Glycometabolic profile: insulin

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

    Change in glycometabolic profile - insulin levels

  3. Body fat mass

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

    Change in body fat mass - bioimpedance analysis

  4. Body fat free mass

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

    Change in body fat free mass - bioimpedance analysis

  5. Body weight

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

    Change in body weight

  6. Body mass index

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

    Change in body mass index

Sponsors and collaborators

Lead sponsor

Istituto Auxologico Italiano

Other

Registry information

Official study title

Biological Age Assessment in Adults With Prader-Willi Syndrome Undergoing an Integrated Multidisciplinary Metabolic Rehabilitation Program

Acronym: ETABIOLPWS

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Mar 21, 2023
Registry last updated
Oct 2, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.